Orchid Pharma FY26 Financials and Strategic Merger Update

Revenue from operations reached Rs 1,232.77 crore for FY 2025-26, while Profit After Tax stood at Rs 9.95 crore.

Reader Takeaway: The company finalized its merger with Dhanuka Laboratories, though investors should note the auditor's qualified opinion on specific foreign subsidiaries.

What just happened

Orchid Pharma officially integrated Dhanuka Laboratories Limited into its operations on July 10, 2026. This move involved the issuance of 4,45,86,052 new equity shares to eligible shareholders in August 2026. The company also reported consolidated financial results for the full fiscal year.

Why this matters

The merger is expected to consolidate technical and managerial resources, strengthening the company's competitive edge. Additionally, the company has secured full global ownership of the Enmetazobactam molecule, now marketed under brand names EXBLIFEP and Orblicef, signaling a focused push into high-value specialty markets.

Operational Progress

The company is betting on backward integration via a new 7-ACA project in Jammu, which is supported by government PLI incentives. Commercial operations for this facility are currently targeted for Q1 2027. On the regulatory front, the Alathur manufacturing facility has successfully cleared a USFDA inspection held in February 2025.

Risks to watch

Statutory auditors M/s. Singhi & Co. issued a qualified opinion on the consolidated financial statements. This stems from the fact that certain US-based subsidiaries (Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals Inc.) were not independently audited, with the consolidation relying on management-provided figures.

Context metrics

• Revenue FY 2024-25: Rs 1,397.61 crore
• Profit After Tax FY 2024-25: Rs 135.07 crore
• Current US DMF filings: 48
• Jammu project land investment: Rs 18.84 crore